COCP Company Profile and Key Details

Q: Who are the executives of COCP?

Mr. James J. Martin CPA, CPA, M.B.A., MBAInterim Co-Chief Executive Officer, Chief Financial Officer & Corporation Sec.Dr. Roger D. Kornberg Ph.D.Co-Founder, Chairman, Chief Scientist & Chairman of Scientific Advisory BoardDr. Sam Lee Ph.D.Co-Founder, Co-Chief Executive Officer & PresMr. James J. Martin C.P.A., CPA, M.B.A., MBACo-Chief Executive Officer, Chief Financial Officer & Corporation Sec.

NASDAQ : COCP

Cocrystal Pharma

$1.51

0.49+48.04%

At Close 4:00 PM

59.2

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Cocrystal Pharma, Inc. (COCP) stock surged +48.04%, trading at $1.51 on NASDAQ, up from the previous close of $1.02. The stock opened at $1.70, fluctuating between $1.36 and $2.03 in the recent session.

Stock Snapshot

1.02

Prev. Close

15.48M

Market Cap

1.36

Day Low

-1.94

P/E Ratio

-0.78

EPS (TTM)

-1.41

Cash Flow per Share

1.7

Open

10.25M

Number of Shares

2.0299

Day High

72.31%

Free Float in %

2.59

Book Value

135.32M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 02, 2026	1.71	2.03	1.36	1.51	135.78M
Apr 01, 2026	1.05	1.08	1.01	1.02	27.95K
Mar 31, 2026	1.00	1.06	1.00	1.01	22.46K
Mar 30, 2026	1.03	1.04	1.00	1.00	71.8K
Mar 27, 2026	1.03	1.06	1.03	1.03	22.61K
Mar 25, 2026	1.08	1.10	1.06	1.08	32.27K
Mar 24, 2026	1.03	1.12	1.03	1.06	48.24K
Mar 23, 2026	1.03	1.11	1.03	1.08	37.57K
Mar 20, 2026	1.09	1.11	1.03	1.03	46.35K
Mar 19, 2026	1.11	1.11	1.07	1.09	16.39K
Mar 18, 2026	1.11	1.14	1.09	1.13	61.65K
Mar 17, 2026	1.05	1.12	1.05	1.11	74.78K
Mar 16, 2026	1.02	1.09	1.00	1.08	120.64K
Mar 13, 2026	1.02	1.05	1.01	1.03	20.04K
Mar 12, 2026	1.05	1.05	1.01	1.01	38.07K
Mar 11, 2026	1.06	1.06	1.01	1.03	24.6K
Mar 10, 2026	1.04	1.07	1.04	1.07	55.05K
Mar 09, 2026	1.03	1.03	0.99	1.03	46.31K
Mar 06, 2026	0.99	1.04	0.99	1.01	17.65K
Mar 03, 2026	1.02	1.06	1.02	1.06	34.38K

Contact Details

Bothell, WA 98011

United States

https://www.cocrystalpharma.com 786 459 1831

About Company

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.

Stock Peers

REGN

-15.4-1.98%

Regeneron Pharmaceuticals, Inc.$761.85 ARGX

3.3+0.44%

argenx SE$746.42 UTHR

-5.46-0.96%

United Therapeutics Corporation$564.81 MDGL

17.05+3.22%

Madrigal Pharmaceuticals, Inc.$546.89 VRTX

-8.55-1.91%

Vertex Pharmaceuticals Incorporated$438.71 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-9.88-3.01%

Alnylam Pharmaceuticals, Inc.$318.85 PRAX

-8.9-2.79%

Praxis Precision Medicines, Inc.$310.38 KRYS

2.04+0.79%

Krystal Biotech, Inc.$260.95 ASND

1.01+0.44%

Ascendis Pharma A/S$229.25

Company Overview

Cocrystal Pharma, Inc. (NASDAQ:COCP) closed at $1.51 USD, gaining $0.49 (48.04%) from the previous close of $1.02. The stock is currently mid-range between its 52-week high and low $0.86 and $2.67. With a market capitalization of about $15.48 million, Cocrystal Pharma, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.18). Key stats such as the average daily volume over the past year has been around 2.26 million shares, trading with heavier-than-usual volume. Headquartered in Bothell, WA, Cocrystal Pharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sam Lee, the company employs approximately 11 people and listed since February 22, 2012. Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 8.9%, SMA50 4.77%, SMA200 -17.7%). The stock’s 14-day RSI is 59.19 (neutral), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -60.3% below its high and over 23.43% above its low. Average 10-day trading volume of 19.43 million shares is significantly above the 3-month average of 2.36 million, indicating heightened recent market interest.

Valuation Metrics

Cocrystal Pharma, Inc. trades at a P/E ratio of -1.93, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.69 suggesting the stock is closer to book value. The P/FCF stands at -1.84, also below market averages.

Dividend & Fair Value

Cocrystal Pharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.49. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Cocrystal Pharma, Inc. generated EPS of -$0.94 over the past year. Five-year average earnings growth is -2.62%. Wall Street analysts project EPS growth of 17.38% annually over the next five years. The latest quarter delivered EPS of -$0.19. The next quarter is forecast at -$0.17. Next year's EPS is expected at -$10.95. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $6.00 to $6.00. The high target offers 297.35% upside. The low target suggests 297.35% downside. The mean target is $6.00. This offers 297.35% upside. Cocrystal Pharma, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 14, 2025, missed forecasts by -13.64%. The prior quarter beat by -15.26%. Over the last six quarters, Apple has recorded several small beats. These include -14.04% in November 13, 2024.

Shareholding & Insider Activity

Cocrystal Pharma, Inc. has 10.26 million shares outstanding. The public float is 6.64 million shares, elevated short interest at 0.53% of float. This equals 41.19 thousand shares. The short ratio is 0.28 days. Institutional investors hold 10.46% of the float. Insiders own 36.05%. WILCOX GARY holds 16.95 million shares, Lee Sam has 13.09 million shares and Schinazi Raymond F has 7.67 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Cocrystal Pharma has not generated any revenue. Returns are negative, with ROA at -57.53% and ROE at -68.16%.
On valuation metrics, Cocrystal Pharma trades at a P/E of -1.93, P/S of 0.00 and P/B of 2.69. The current ratio is 3.68 and quick ratio is 3.68. Debt-to-equity is 0.24, supported by a cash flow-to-debt ratio of -5.57.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Cocrystal Pharma posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was $1.39M (margin 0.00%). Operating income was - $21.16M (margin 0.0%). Net income was- $17.98M (EPS - $1.86).
The company ended the quarter with $26.43M in cash and short-term investments, a total debt of $1.85M, and net debt of - $24.58M. Total assets were $31.26M, with equity of $26.38M. Financials further reflected weakness, with operating cash flow of - $14.67M, free cash flow of - $14.78M, and capital expenditures of - $118.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Cocrystal Pharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -11.92%, with price expected at $1.33 by April 16, 2026, within a range of $1.25 to $1.41 3-Month Outlook: Projected rise of 8.61%, reaching $1.64 by July 01, 2026, with a range of $1.56 to $1.72. 1-Year Outlook: Projected gain of 378.81%, with price at $7.23 by April 02, 2027, within a range of $1.05 to $8.96.

Key Takeaways

Cocrystal Pharma, Inc. (NASDAQ:COCP) shares are flat 7.25% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Cocrystal Pharma, Inc. trading at a premium to the broader market with a P/E of -1.93. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $14.33, suggesting 849.01% upside. Our AI forecast model points to short-term weakness (-11.92% over two weeks), a medium-term rise (8.61% over three months), and a longer-term gain (378.81% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Cocrystal Pharma, Inc. (COCP) stock price?

Cocrystal Pharma, Inc. (NASDAQ: COCP) stock price is $1.51 in the last trading session. During the trading session, COCP stock reached the peak price of $2.03 while $1.36 was the lowest point it dropped to. The percentage change in COCP stock occurred in the recent session was 48.04% while the dollar amount for the price change in COCP stock was $0.49.

COCP's industry and sector of operation?

The NASDAQ listed COCP is part of Biotechnology industry that operates in the broader Healthcare sector. Cocrystal Pharma, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of COCP?

Mr. James J. Martin CPA, CPA, M.B.A., MBA
Interim Co-Chief Executive Officer, Chief Financial Officer & Corporation Sec.
Dr. Roger D. Kornberg Ph.D.
Co-Founder, Chairman, Chief Scientist & Chairman of Scientific Advisory Board
Dr. Sam Lee Ph.D.
Co-Founder, Co-Chief Executive Officer & Pres
Mr. James J. Martin C.P.A., CPA, M.B.A., MBA
Co-Chief Executive Officer, Chief Financial Officer & Corporation Sec.

How COCP did perform over past 52-week?

COCP's closing price is 75.58% higher than its 52-week low of $0.86 where as its distance from 52-week high of $2.67 is -43.45%.

How many employees does COCP have?

Number of COCP employees currently stands at 11.

Link for COCP official website?

Official Website of COCP is: https://www.cocrystalpharma.com

How do I contact COCP?

COCP could be contacted at phone 786 459 1831 and can also be accessed through its website. COCP operates from 19805 North Creek Parkway, Bothell, WA 98011, United States.

How many shares of COCP are traded daily?

COCP stock volume for the day was 135.32M shares. The average number of COCP shares traded daily for last 3 months was 2.26M.

What is the market cap of COCP currently?

The market value of COCP currently stands at $15.48M with its latest stock price at $1.51 and 10.25M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	11
Beta	1.22
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

COCP Company Profile and Key Details

Cocrystal Pharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways

Company Overview